$CRVO
CervoMed Inc.

2018 Q1 Form 10-Q Financial Statement

#000143774918009433 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.500M $1.550M
YoY Change -3.23% -59.84%
% of Gross Profit
Research & Development $1.826M $1.008M
YoY Change 81.19% -57.18%
% of Gross Profit
Depreciation & Amortization $28.02K $6.603K
YoY Change 324.32% -33.97%
% of Gross Profit
Operating Expenses $1.826M $1.008M
YoY Change 81.19% -57.18%
Operating Profit -$3.351M -$2.567M
YoY Change 30.54% -58.75%
Interest Expense $37.46K $55.72K
YoY Change -32.76% 265228.57%
% of Operating Profit
Other Income/Expense, Net $0.00 -$13.10M
YoY Change -100.0%
Pretax Income -$3.314M -$28.64M
YoY Change -88.43% 360.45%
Income Tax
% Of Pretax Income
Net Earnings -$3.314M -$28.64M
YoY Change -88.43% 360.2%
Net Earnings / Revenue
Basic Earnings Per Share -$4.11
Diluted Earnings Per Share $2.814M -$41.51M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.20M $12.21M
YoY Change 32.68% 108.01%
Cash & Equivalents $16.20M $12.21M
Short-Term Investments
Other Short-Term Assets $890.0K $140.0K
YoY Change 535.71% -64.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.09M $20.63M
YoY Change -17.17% 230.06%
LONG-TERM ASSETS
Property, Plant & Equipment $432.6K $79.52K
YoY Change 444.03% -23.29%
Goodwill $6.929M $6.929M
YoY Change 0.0% -2.47%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $275.7K $63.82K
YoY Change 332.05% -52.47%
Total Long-Term Assets $16.28M $15.71M
YoY Change 3.6% -5.69%
TOTAL ASSETS
Total Short-Term Assets $17.09M $20.63M
Total Long-Term Assets $16.28M $15.71M
Total Assets $33.37M $36.34M
YoY Change -8.19% 58.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $419.1K $557.6K
YoY Change -24.84% -50.21%
Accrued Expenses $450.0K $1.020M
YoY Change -55.88% -6.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $550.0K $1.880M
YoY Change -70.74%
Total Short-Term Liabilities $1.423M $51.60M
YoY Change -97.24% 2237.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $550.0K
YoY Change -100.0% 0.0%
Other Long-Term Liabilities $33.31K
YoY Change -11.82%
Total Long-Term Liabilities $0.00 $33.31K
YoY Change -100.0% -11.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.423M $51.60M
Total Long-Term Liabilities $0.00 $33.31K
Total Liabilities $3.646M $55.46M
YoY Change -93.43% 775.86%
SHAREHOLDERS EQUITY
Retained Earnings -$64.87M -$88.83M
YoY Change -26.97% 83.62%
Common Stock $94.59M $69.71M
YoY Change 35.69% 7.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.72M -$19.12M
YoY Change
Total Liabilities & Shareholders Equity $33.37M $36.34M
YoY Change -8.19% 58.63%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$3.314M -$28.64M
YoY Change -88.43% 360.2%
Depreciation, Depletion And Amortization $28.02K $6.603K
YoY Change 324.32% -33.97%
Cash From Operating Activities -$3.289M -$3.416M
YoY Change -3.71% -26.23%
INVESTING ACTIVITIES
Capital Expenditures $6.372K
YoY Change 219.56%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$6.372K
YoY Change -100.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.85M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.59M 14.08M
YoY Change -24.78%
NET CHANGE
Cash From Operating Activities -3.289M -3.416M
Cash From Investing Activities -6.372K
Cash From Financing Activities 10.59M 14.08M
Net Change In Cash 7.303M 10.66M
YoY Change -31.49% 175.54%
FREE CASH FLOW
Cash From Operating Activities -$3.289M -$3.416M
Capital Expenditures $6.372K
Free Cash Flow -$3.289M -$3.422M
YoY Change -3.89% -26.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
55210
CY2017Q4 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
63350
CY2018Q1 dffn Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
CY2018Q1 dffn Dividends Makewhole Adjustment
DividendsMakewholeAdjustment
8200000
CY2018Q1 dffn Dividends Makewhole Adjustment
DividendsMakewholeAdjustment
8167895
CY2017Q1 dffn Dividends Makewhole Adjustment
DividendsMakewholeAdjustment
CY2018Q1 dffn Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
174777
CY2017Q1 dffn Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
178258
CY2018Q1 dffn Preferential Dividends Payble
PreferentialDividendsPayble
CY2017Q4 dffn Preferential Dividends Payble
PreferentialDividendsPayble
1062314
CY2018Q1 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
890891
CY2017Q4 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
769946
CY2018Q1 dffn Proceeds From Issuance Of Convertible Preferred Stock Net Of Offering Costs
ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts
CY2017Q1 dffn Proceeds From Issuance Of Convertible Preferred Stock Net Of Offering Costs
ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts
14269095
CY2017Q1 dffn Warrant Expense Change In Fair Value And Other Financing Expenses
WarrantExpenseChangeInFairValueAndOtherFinancingExpenses
-26015746
CY2018Q1 dffn Reclassification Of Deferred Offering Costs Upon Completion Of Private Placement
ReclassificationOfDeferredOfferingCostsUponCompletionOfPrivatePlacement
CY2017Q1 dffn Reclassification Of Deferred Offering Costs Upon Completion Of Private Placement
ReclassificationOfDeferredOfferingCostsUponCompletionOfPrivatePlacement
180456
CY2018Q1 dffn Stock And Warrants Issued During Period Value Net Issuance Costs
StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
10417520
CY2018Q1 dffn Reclassification Of Accrued Dividends Related To Issuance Of Common Stock To Preferred Stock Holders
ReclassificationOfAccruedDividendsRelatedToIssuanceOfCommonStockToPreferredStockHolders
1148307
CY2017Q1 dffn Reclassification Of Accrued Dividends Related To Issuance Of Common Stock To Preferred Stock Holders
ReclassificationOfAccruedDividendsRelatedToIssuanceOfCommonStockToPreferredStockHolders
CY2018Q1 dffn Stock Issued During Period Shares Makewhole Adjustment
StockIssuedDuringPeriodSharesMakewholeAdjustment
11668421
CY2018Q1 dffn Stock Issued During Period Value Makewhole Adjustment
StockIssuedDuringPeriodValueMakewholeAdjustment
CY2018Q1 dffn Warrant Expense
WarrantExpense
CY2017Q1 dffn Warrant Expense
WarrantExpense
10225846
CY2018Q1 dffn Warrant Expense Change In Fair Value And Other Financing Expenses
WarrantExpenseChangeInFairValueAndOtherFinancingExpenses
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
419103
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
511956
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
85235
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
122711
CY2018Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
184689
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
312221
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
94538808
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82770313
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
324667
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324667
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
366383
CY2018Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1356
CY2017Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
57185
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34977433
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29471085
CY2018Q1 us-gaap Assets
Assets
33366978
CY2017Q4 us-gaap Assets
Assets
26145815
CY2018Q1 us-gaap Assets Current
AssetsCurrent
17090372
CY2017Q4 us-gaap Assets Current
AssetsCurrent
9666414
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16199481
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8896468
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1552852
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12212025
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7303013
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10659173
CY2018Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
31707233
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
1032219
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14519629
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50526547
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14519629
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50526547
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2223678
CY2018Q1 us-gaap Depreciation
Depreciation
28018
CY2017Q1 us-gaap Depreciation
Depreciation
6603
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
50526
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
14520
CY2018Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
550000
CY2017Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
550000
CY2018Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
28018
CY2017Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
6603
CY2018Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2223678
CY2018Q1 us-gaap Dividends
Dividends
85993
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.78
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12919674
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1497839
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1553139
CY2018Q1 us-gaap Goodwill
Goodwill
6929258
CY2017Q4 us-gaap Goodwill
Goodwill
6929258
CY2018Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2018Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2017Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-236420
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1123303
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
92944
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
99737
CY2018Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8639000
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8639000
CY2018Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
37464
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-55719
CY2018Q1 us-gaap Interest Payable Current
InterestPayableCurrent
38771
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
37415
CY2018Q1 us-gaap Liabilities
Liabilities
3646494
CY2017Q4 us-gaap Liabilities
Liabilities
4915871
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33366978
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26145815
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1422816
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2690807
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10592297
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14081446
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6372
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3289284
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3415901
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3313961
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-28638778
CY2018Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-left:0.6%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align:top;width:9%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div></div> </td> <td style="vertical-align:top;width:91%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Organization and Description of Business</div></div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 44pt;">Diffusion Pharmaceuticals Inc. (&#x201c;Diffusion&#x201d; or &#x201c;the Company&#x201d;, &#x201c;we&#x201d; or &#x201c;us&#x201d;), a Delaware corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (&#x201c;TSC&#x201d;), for use in the many cancer types in which tumor oxygen deprivation (&#x201c;hypoxia&#x201d;) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer&#x2019;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy.</div></div>
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11567849
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28697623
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3351425
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2567313
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
473735
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
118519
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
116464
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
114409
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
39735
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
84608
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
453713
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1628851
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
275714
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
450491
CY2018Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1386
CY2018Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
CY2017Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2870226
CY2018Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
89808
CY2017Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
30840
CY2018Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
253765
CY2017Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
187649
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6372
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10846062
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
432634
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
460652
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1825568
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1007571
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64868850
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61554889
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
324667
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
366383
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.127
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2011881
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.84
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2192
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
500000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2555989
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3053797
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.32
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29720484
CY2018Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.30
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
17.10
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.18
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y240D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y167D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y131D
CY2018Q1 us-gaap Stock Issued1
StockIssued1
CY2017Q1 us-gaap Stock Issued1
StockIssued1
8280935
CY2018Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
8306278
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
1148307
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
29720484
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21229944
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
21229944
CY2018Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
85993
CY2017Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
58845
CY2018Q1 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2017Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
16778682
CY2018Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
13750000
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
13750000
CY2018Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
12376329
CY2018Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
8306278
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 8pt;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 44pt;">The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim condensed consolidated financial statements in the period they are determined necessary.</div></div></div></div></div></div></div></div>
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42122395
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10337726

Files In Submission

Name View Source Status
0001437749-18-009433-index-headers.html Edgar Link pending
0001437749-18-009433-index.html Edgar Link pending
0001437749-18-009433.txt Edgar Link pending
0001437749-18-009433-xbrl.zip Edgar Link pending
dffn-20180331.xml Edgar Link completed
dffn-20180331.xsd Edgar Link pending
dffn-20180331_cal.xml Edgar Link unprocessable
dffn-20180331_def.xml Edgar Link unprocessable
dffn-20180331_lab.xml Edgar Link unprocessable
dffn-20180331_pre.xml Edgar Link unprocessable
dffn20180331_10q.htm Edgar Link pending
ex_113221.htm Edgar Link pending
ex_113222.htm Edgar Link pending
ex_113223.htm Edgar Link pending
ex_113224.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending